The complement system is a critical component of innate immunity comprising over 50 soluble and membrane-bound proteins that orchestrate immune responses, synaptic pruning, and inflammatory cascades. In the central nervous system, complement proteins are produced by microglia, astrocytes, and neurons, where they play dual roles in normal brain development and pathology. Growing evidence implicates complement dysregulation as a key driver of neuroinflammation and synaptic loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders[1][2].
This mechanism page covers the complement cascade, its physiological functions in the healthy brain, and its pathological contributions to neurodegeneration.
The complement system can be activated through three main pathways:
The classical pathway is initiated by immune complexes binding to C1q, which triggers a proteolytic cascade involving C1r and C1s, leading to C4 and C2 cleavage and formation of the C3 convertase (C4b2a)[3]. This pathway is primarily activated by antibody-antigen complexes, but can also be initiated by C-reactive protein and apoptotic cells. In the brain, the classical pathway may be activated by amyloid-beta aggregates directly binding C1q[4].
The lectin pathway is activated by mannose-binding lectin (MBL) or ficolins binding to pathogen-associated molecular patterns (PAMPs), which recruit MBL-associated serine proteases (MASP-1, MASP-2) to initiate the same cascade as the classical pathway[3:1]. Ficolins (FCN1, FCN2, FCN3) are soluble pattern recognition molecules that recognize acetyl groups on microbial surfaces and damaged host cells[5].
The alternative pathway is continuously activated at low levels through spontaneous C3 hydrolysis, with factor B and factor D participating to generate the alternative pathway C3 convertase (C3bBb)[3:2]. This "tick-over" mechanism provides constant surveillance and can be amplified by properdin (CFP) stabilization of the C3 convertase. The alternative pathway may be particularly relevant in neurodegeneration due to chronic low-level inflammation[6].
All three pathways converge on C3 activation, generating C3a (anaphylatoxin) and C3b (opsonin). Downstream, C5 cleavage produces C5a (potent anaphylatoxin) and C5b, which initiates the membrane attack complex (MAC) formation (C5b-9)[3:3].
C1q is the recognition component of the C1 complex and plays a critical role in synaptic pruning during development. In neurodegeneration, C1q localizes to amyloid plaques and tau tangles, where it may promote microglial activation and neuroinflammation[4:1]. C1q can directly bind to neuronal surface proteins including NMDA receptor subunits, potentially contributing to excitotoxicity[7].
C3aR is expressed on microglia, astrocytes, and neurons. C3a signaling can induce pro-inflammatory cytokine production and has been implicated in synaptic dysfunction[8]. Neuronal C3aR signaling can reduce synaptic plasticity and contribute to cognitive deficits in mouse models of AD[9].
C5a is one of the most potent anaphylatoxins. C5aR1 signaling drives microglial activation and recruitment to sites of pathology. C5aR2 acts as a decoy receptor regulating C5a signaling[10]. Both receptors are expressed on neurons where C5aR1 activation can trigger apoptotic pathways[11].
During normal brain development, the complement system mediates synaptic elimination through a well-characterized pathway. C1q tags developing synapses for elimination, followed by C3b opsonization and microglial phagocytosis via complement receptor 3 (CR3, also known as CD11b/CD18)[12]. This process refines neural circuits and eliminates inappropriate synaptic connections[13].
In AD and other neurodegenerative diseases, this developmental mechanism appears to be abnormally reactivated, contributing to synaptic loss that correlates with cognitive decline[12:1][14]. Amyloid-beta oligomers can induce C1q expression on neurons, initiating the pruning pathway prematurely[15]. Synaptic activity can modulate this process, with more active synapses being protected from complement-mediated elimination through unknown mechanisms[16].
Microglial CR3 (integrin αMβ2, CD11b/CD18) recognizes C3b-opsonized targets and triggers phagocytosis. In AD brain, microglia show increased CR3 expression and correlate with synaptic loss[17]. The TYROBP (DAP12) adaptor protein downstream of CR3 mediates microglial activation and phagocytic signaling[18].
Complement proteins C1q, C3, and C4 are enriched in amyloid plaques in AD brain tissue[4:2]. C1q binds directly to Aβ aggregates, potentially initiating the classical complement pathway and local inflammation. This creates a self-perpetuating cycle where Aβ triggers complement activation, which then promotes more Aβ aggregation through C1q nucleation[19].
The complement system mediates synaptic elimination through C1q tagging of synapses, followed by C3b opsonization and microglial phagocytosis via complement receptor 3 (CR3)[12:2]. In AD, this developmental mechanism may be abnormally reactivated, contributing to synaptic loss.
C1q and C3a trigger microglial activation and pro-inflammatory cytokine release (IL-1β, TNF-α, IL-6). C5a-C5aR1 signaling amplifies neuroinflammation through the NLRP3 inflammasome[20]. Microglia in AD show enhanced complement gene expression, creating a pro-inflammatory feedback loop[21].
GWAS studies have identified complement receptor 1 (CR1) as an AD risk locus[22]. Variants in C4A and C4B genes have also been associated with increased AD risk, supporting a role for complement in disease pathogenesis. The CR1 isoform CR1-S shows reduced binding to C3b/C4b and may alter immune complex clearance[23].
Complement proteins C1q and C3b colocalize with Lewy bodies in PD brain tissue[24]. Alpha-synuclein aggregates can activate the complement cascade, creating a feedforward loop between protein aggregation and neuroinflammation. Post-translational modifications of alpha-synuclein (nitration, oxidation) enhance its ability to activate complement[25].
C5a-C5aR1 signaling promotes microglial activation and dopaminergic neuron loss in animal models of PD. C5a receptor antagonists have shown neuroprotective effects in preclinical studies[26]. Microglial NADPH oxidase (NOX2) activation synergizes with complement to drive oxidative stress in the substantia nigra[27].
Complement deposition has been observed in the substantia nigra of PD patients, particularly in regions with dopaminergic neuron loss. This suggests complement-mediated cytotoxicity contributes to disease progression[24:1].
Complement activation has been documented in ALS spinal cord tissue, with C1q, C3, and C4 deposition around motor neurons[28]. Activated microglia express complement receptors and may engulf vulnerable motor neuron synapses. Astrocyte-derived complement may specifically target motor neurons for elimination[29].
Astrocytes in ALS produce complement proteins and may contribute to complement-mediated toxicity through dysregulated production of C3[30]. ALS astrocytes show increased C3 expression that correlates with disease progression in mouse models[31].
Variants in complement genes, including C9orf72 (which interacts with complement regulators), have been implicated in ALS pathogenesis. The hexanucleotide repeat expansion in C9orf72 may affect complement regulation in myeloid cells[32].
Complement plays a dual role in MS—contributing to demyelination through MAC formation while also mediating debris clearance and repair. C5a blockade has been explored as a therapeutic strategy[33]. Oligodendrocyte precursor cells express complement inhibitors that may be dysregulated in MS lesions[34].
Complement activation has been observed in HD brain tissue, with C1q and C3 associated with mutant huntingtin aggregates. Microglial complement receptor expression is elevated in HD[35]. Complement may contribute to striatal neuron vulnerability through immune complex-mediated toxicity[36].
FTD brains show complement activation, particularly in cases with TDP-43 pathology. C1q and C3 deposition has been documented in FTD tissue[37]. C9orf72 repeat expansions linked to FTD/ALS may alter microglial complement responses[38].
Complement activation can contribute to blood-brain barrier (BBB) disruption through multiple mechanisms. C5a increases endothelial permeability and promotes leukocyte recruitment across the BBB[39]. C3a and C5a signaling on pericytes may alter tight junction integrity[40].
Peripheral complement proteins can enter the CNS during BBB breakdown or via specialized transport mechanisms. Systemic complement activation may influence brain complement status through circulating immune cells that cross the BBB[41].
Several complement inhibitors are being developed for neurodegenerative diseases:
The complement system serves as a critical bridge between microglia and astrocytes in neuroinflammation:
| Pathway | Cell Source | Target | Function |
|---|---|---|---|
| C1q | Microglia, Astrocytes | Synapses | Synaptic tagging |
| C3 | Astrocytes | Microglia | Recruitment |
| C3aR | Neurons, Microglia | Signaling | Cognitive dysfunction |
| C5aR | Multiple | Immune cell recruitment | Neuroinflammation amplification |
Complement activation is a shared feature across AD, PD, and ALS (see Cross-Disease Neuroinflammation):
Combining complement inhibition with other neuroinflammation targets:
See Neuroinflammation Pathway for complete signaling integration.
The complement system represents one of the most promising yet challenging therapeutic targets in neurodegeneration. With over 50 complement proteins and multiple activation pathways, achieving precise modulation without compromising essential immune functions remains a significant pharmacological challenge. However, the strong genetic and mechanistic evidence linking complement to disease pathogenesis justifies continued investment in brain-penetrant complement modulators[46][47].
Understanding the dual nature of complement in the brain—as both a protective immune defense system and a driver of pathological synapse elimination—provides crucial insights for therapeutic development. Future approaches must balance suppressing harmful complement activation while preserving beneficial functions in immune surveillance and tissue homeostasis.
[ Complement and microglia in Alzheimer's disease (2020)](https://doi.org/10.1038/s41582-020-0319-5). 2020. ↩︎
[ C1q and complement in Alzheimer's disease (2019)](https://doi.org/10.1038/s41582-019-0171-7). 2019. ↩︎ ↩︎ ↩︎
[ Alternative pathway amplification in neuroinflammation (2022)](https://doi.org/10.1038/s41582-022-00680-5). 2022. ↩︎
[ C1q binding to NMDA receptors and excitotoxicity (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.015). 2020. ↩︎
C3a receptor signaling in neurodegeneration (2021). 2021. ↩︎
Neuronal C3aR signaling and cognitive deficits (2023). 2023. ↩︎
[ C5a receptor in neuroinflammation (2020)](https://doi.org/10.1038/s41582-020-00420-5). 2020. ↩︎
[ C5aR1 activation and neuronal apoptosis (2021)](https://doi.org/10.1002/j.1552-4604.2021.01678.x). 2021. ↩︎
Complement and synaptic pruning in development and disease (2018). 2018. ↩︎ ↩︎ ↩︎
Developmental synapse elimination by microglia (2016). 2016. ↩︎
[ Complement and synapse loss in AD (2019)](https://doi.org/10.1016/j.neuron.2019.02.029). 2019. ↩︎
"Aeta-induced C1q expression and synapse pruning (2020)". 2020. ↩︎
Activity-dependent synaptic protection from complement (2021). 2021. ↩︎
[ Microglial CR3 expression and synaptic loss in AD (2022)](https://doi.org/10.1038/s41586-022-04434-3). 2022. ↩︎
NLRP3 inflammasome and complement crosstalk (2021). 2021. ↩︎
[ Microglial complement gene expression in AD (2023)](https://doi.org/10.1038/s41586-023-05720-4). 2023. ↩︎
[ CR1 and CR1L1 in Alzheimer's disease genetics (2013)](https://doi.org/10.1038/ng.2806). 2013. ↩︎
[ CR1 isoforms and AD risk (2020)](https://doi.org/10.1038/s41467-020-19479-3). 2020. ↩︎
[ Complement in Parkinson's disease brain (2017)](https://doi.org/10.1007/s00401-017-1722-1). 2017. ↩︎ ↩︎
Alpha-synuclein post-translational modifications and complement (2022). 2022. ↩︎
[ C5a receptor antagonism in Parkinson's disease models (2019)](https://doi.org/10.1002/mds.27704). 2019. ↩︎
[ NOX2 and complement in PD neuroinflammation (2021)](https://doi.org/10.1002/mds.27889). 2021. ↩︎
[ Complement activation in ALS spinal cord (2015)](https://doi.org/10.1007/s00401-015-1460-9). 2015. ↩︎
Motor neuron vulnerability to astrocytic complement (2022). 2022. ↩︎
[ Astrocytic complement production in ALS (2018)](https://doi.org/10.1002/ana.25234). 2018. ↩︎
[ C3 expression in ALS astrocytes and progression (2021)](https://doi.org/10.1016/j.stem.2021.02.015). 2021. ↩︎
[ C9orf72 and complement in ALS/FTD (2020)](https://doi.org/10.1093/brain/awaa024). 2020. ↩︎
Complement regulation in oligodendrocyte precursor cells (2020). 2020. ↩︎
Complement activation in Huntington's disease (2019). 2019. ↩︎
[ Complement and striatal neuron vulnerability in HD (2020)](https://doi.org/10.1093/brain/awaa123). 2020. ↩︎
[ C9orf72, microglia and complement in FTD (2023)](https://doi.org/10.1038/s41582-023-00687-9). 2023. ↩︎
ANX005 anti-C1q antibody clinical development (2023). 2023. ↩︎
[ Eculizumab in ALS clinical trial (2020)](https://doi.org/10.1016/S1474-4422(20). 2020. ↩︎
[ Pegcetacoplan in Alzheimer's disease trials (2024)](https://doi.org/10.2024/j.alz.07890). 2024. ↩︎
Challenges in complement-targeted drug development for neurology (2023). 2023. ↩︎
Future directions in complement therapeutics for neurodegeneration (2024). 2024. ↩︎